Clinical Trial

DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is designed to evaluate safety and antitumor activity of DZD6008 combination therapy in patients with advanced Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-08.
Status change: Not Yet Recruiting → Recruiting 2025-08-25
Trial Details
NCT Number NCT07070440
Lead Sponsor Dizal Pharmaceuticals
Conditions Non Small Cell Lung Cancer
Enrollment 100 participants
Start Date 2025-07-16
Primary Completion 2027-06 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-08-29